<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280305</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-10-8287-MW-SHEBA</org_study_id>
    <nct_id>NCT01280305</nct_id>
  </id_info>
  <brief_title>Raloxifene in Treatment of Schizophrenia and Schizoaffective Disorder</brief_title>
  <acronym>RAL-S-01</acronym>
  <official_title>A Randomized Trial Administering Raloxifene vs Placebo as add-on to Antipsychotics in Post Menopausal Patients With Schizophrenia or Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the efficacy of raloxifene compared to placebo, as
      add-on to anti-psychotics in the treatment of post menopausal patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological evidence shows a potentially protective role for estrogen in women with
      schizophrenia. The onset of schizophrenia is later in woman than in men, with generally a
      less severe course until after the menopause, when for many women, reductions in estrogen
      levels appear to trigger an exacerbation or illness (Hafner 2003). ERÎ± (Estrogen receptor
      alpha) expression is known to be reduced in schizophrenia (Wong, Woon et al. 2010).
      Raloxifene is a selective estrogen receptor modulator that acts as an estrogen antagonist in
      breast tissue and may have agonistic actions in the brain. Several studies (Kulkarni, Riedel
      et al. 2001; Chua, de Izquierdo et al. 2005; Kulkarni, Gurvich et al. 2010) indicate that
      treatment with estrogen and raloxifene improves symptoms in females with schizophrenia, and
      recently they showed an improvement in PANSS score in post menopausal women with
      schizophrenia receiving 60-120mg/d of raloxifene compared to placebo
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PANSS total score at the end of the trial.</measure>
    <time_frame>3 times</time_frame>
    <description>PANSS will be assesed at weeks 5, 8 and end of study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS,CGI-S, CGI-I, BACS and rates of drop outs before the end of the trial.</measure>
    <time_frame>PANSS 3 times, CGI-S and CGI-I 5 times and BACS 2 times</time_frame>
    <description>PANSS will be assessed at week 5, 8, and end of study; CGI-S, CGI-I, will be assessed at week 2, 5, 8, 12, and end of study; BACS will be assessed at week 8 and end of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>raloxifene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raloxifene</intervention_name>
    <description>raloxifene 60 mg bid</description>
    <arm_group_label>raloxifene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo bid</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Post menopausal females: Post menopausal defined as: Women 45 years of age and older
             with no vaginal bleeding for at least 2 years prior to randomization, and both serum
             estradiol &lt;73 pmol/L (20 pg/mL) and FSH &gt;30 IU/L (30 mIU/mL).

          2. 45-65 years old

          3. Willing and able to provide informed consent, after the nature of the study has been
             fully explained.

          4. Current DSM-IV-TR diagnosis of schizophrenia or schizoaffective disorder as confirmed
             by modified SCID and having had at least 2 prior schizophrenic episodes, or
             continually ill for at least 6 months.

          5. Symptoms: 4 (moderate) or above on CGI-S and 4 (moderate) score or above on two of the
             following four PANSS items: delusions, hallucinatory behaviors, conceptual
             disorganization or suspiciousness/ persecution, and/or a total PANSS negative symptoms
             score of 18.

          6. Must be on any antipsychotic drug, for at least 2 weeks prior to the baseline visit,
             at doses within the PORT criteria, whenever possible. Patients receiving higher doses
             will have their records reviewed to insure that the dose is required and, if possible,
             will be stabilized on a lower dose prior to study entry.

          7. Inpatients or outpatients. Inpatients will be randomized 3 days or more after
             admission.

        Exclusion Criteria:

          1. Unwilling or unable, in the opinion of the Investigator, to comply with study
             instructions

          2. Women of child bearing potential.

          3. Women who have amenorrhea due to causes other than natural or surgical menopause i.e.
             eating disorders or exercise

          4. Unstable medical disease (malignancy, poorly controlled diabetes, active ischemic
             cardiac disease, or cardiomyopathy, serious pulmonary disease, kidney disease,
             impaired liver functioning.

          5. Patients treated with cholestyramine, warfarin or concurrent systemic estrogen therapy

          6. Likely allergy or sensitivity to raloxifene.

          7. At significant risk of committing suicide, or in the opinion of the Investigator,
             currently is at imminent risk of suicide or harming others.

          8. Patients with a current DSM-IV substance or alcohol abuse. Patients with a history of
             and/or current recreational use of cannabinoids or alcohol, and/or patients who smoke
             cigarettes can be included.

          9. Concurrent delirium, mental retardation, drug-induced psychosis, or history of brain
             trauma.

         10. Patients with hypercoaguable conditions or risk of venous thrombosis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Weiser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Weiser, MD</last_name>
    <phone>972-52-666-6575</phone>
    <email>mweiser@netvision.net.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Weiser, MD</last_name>
      <phone>972-52-666-6575</phone>
      <email>mweiser@netvision.net.il</email>
    </contact>
    <investigator>
      <last_name>Mark Weiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica de Psihiatrie, Arad</name>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Delia Podea, MD</last_name>
      <phone>0722 583 757</phone>
      <email>deliapodea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Delia Podea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul de Psihiatrie Botosani</name>
      <address>
        <city>Botosani</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan Prelipceanu, MD</last_name>
      <phone>0722 300 227</phone>
      <email>prelipceanudan@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dan Prelipceanu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriela Marian, MD</last_name>
      <phone>0723 569 620</phone>
      <email>gabi.marian@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Gabriela Marian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Ladea, MD</last_name>
      <phone>0724 371 042</phone>
      <email>marialadea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Ladea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dorina-Valerica Sima, MD</last_name>
      <phone>0723 859 570</phone>
      <email>dorinasima@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Dorina-Valerica Sima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria-Silvia Trandafir, MD</last_name>
      <phone>0724 275 572</phone>
      <email>silviatrandafir2004@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Maria-Silvia Trandafir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana-Liana Giurgiuca, MD</last_name>
      <phone>0722 378 967</phone>
      <email>giurgiuca_liana@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ana-Liana Giurgiuca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Alex. Obregia&quot;</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valentin Matei, MD</last_name>
      <phone>0723 640 918</phone>
      <email>petcu_camelia@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Valentin Matei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sp. Jud. &quot;Prof. Dr.O. Fodor&quot;</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mircea-Alexandru Birt, MD</last_name>
      <phone>0721 012 220</phone>
      <email>mirceabirt@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mircea-Alexandru Birt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj</name>
      <address>
        <city>Cluj</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ioana-Valentina Miclutia, MD</last_name>
      <phone>0722 796 067</phone>
      <email>ioanamiclu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ioana-Valentina Miclutia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie Socola, Iasi</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serban Turliuc, MD</last_name>
      <phone>0745 203 002</phone>
      <email>serban_turliuc@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Serban Turliuc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>January 19, 2011</last_update_submitted>
  <last_update_submitted_qc>January 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mark Weiser MD</name_title>
    <organization>Sheba Medical Center</organization>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raloxifene Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

